A phase I, open-label study of the safety, tolerability and pharmacokinetics of lapatinib (GW572016) in combination with trastuzumab

被引：0
|
作者：
Storniolo, AM
Burris, HA
Overmoyer, B
Silverman, P
Pegram, MD
Jones, SF
Peacock, NW
Loftiss, J
Koch, KM
Paul, E
Ho, PTC
机构：
[1] Indiana Univ, Ctr Canc, Indianapolis, IN 46204 USA
[2] Sarah Cannon Canc Ctr, Nashville, TN USA
[3] Case Western Reserve Univ, Ireland Canc Ctr, Cleveland, OH 44106 USA
[4] Univ Calif Los Angeles, Ctr Hlth Sci, Los Angeles, CA 90024 USA
[5] GSK, Res Triangle Pk, NC USA
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2005年 / 94卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S64 / S64
页数：1
相关论文
共 50 条
  • [1] A phase I, open-label study of the safety, tolerability and pharmacokinetics of lapatinib (GW572016) in combination with trastuzumab.
    Burris, H
    Storniolo, AM
    Overmoyer, EA
    Pegram, MD
    Jones, SF
    Peacock, NW
    Loftiss, JI
    Koch, KM
    Paul, E
    Beelen, AP
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S126 - S126
  • [2] A phase I, open-label study of the safety, tolerability and pharmacokinetics of lapatinib (GW572016) in combination with letrozole in cancer patients
    Chu, Q
    Cianfrocca, ME
    Murray, N
    Oslund, M
    Nelson, LM
    Rowinsky, E
    Schwartz, G
    Goldstein, LJ
    Loftiss, JI
    Paul, E
    Koch, KM
    Pandite, L
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S235 - S235
  • [3] A phase I, open-label study of the safety, tolerability and pharmacokinetics of lapatinib (GW572016) in combination with letrozole in cancer patients.
    Chu, Q
    Goldstein, L
    Murray, N
    Rowinsky, E
    Cianfrocca, M
    Gale, M
    Ho, P
    Paul, E
    Loftiss, J
    Pandite, L
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 192S - 192S
  • [4] A phase 1, open-label study of lapatinib (GW572016) plus trastuzumab; a clinically active regimen.
    Storniolo, AM
    Burris, H
    Pegram, M
    Overmoyer, B
    Miller, K
    Jones, S
    Silverman, P
    Paul, E
    Loftiss, J
    Pandite, L
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 18S - 18S
  • [5] Phase I study of lapatinib (GW572016) in combination with letrozole in cancer patients
    Chu, Q.
    Rowinsky, E.
    Goldstein, L.
    Cianfrocca, M.
    Murray, N.
    Gale, M.
    Ho, P. T.
    Loftiss, J. I.
    Paul, E.
    Pandite, L.
    EJC SUPPLEMENTS, 2005, 3 (02): : 119 - 119
  • [6] Phase I study of lapatinib (GW572016) in combination with trastuzumab in advanced ErbB2-positive breast cancer
    Storniolo, A. M.
    Burris, H. A., III
    Pegram, M. D.
    Overmoyer, B.
    Miller, K.
    Jones, S. F.
    Silverman, P.
    Paul, E.
    Loftiss, J.
    Pandite, L.
    EJC SUPPLEMENTS, 2005, 3 (02): : 78 - 78
  • [7] A phase II, open-label, multicenter study of lapatinib (GW572016) in patients with metastatic breast cancer that has progressed on trastuzumab-containing reimens
    Blackwell, Kimberly
    Kaplan, Edward H.
    Franco, Sandra X.
    Marcom, P. Kelly
    Maleski, Janet
    Sorensen, Mel
    Berger, Mark S.
    ANNALS OF ONCOLOGY, 2004, 15 : 27 - 27
  • [8] A phase I study of lapatinib (GW572016) and topotecan in patients with solid tumors
    Molina, JRM
    Adjei, AA
    Erlichman, C
    Mandrekar, S
    Joy, ME
    Rubin, SD
    Reid, J
    ANNALS OF ONCOLOGY, 2006, 17 : 49 - 49
  • [9] Phase I pharmacokinetic study of the safety and tolerability of lapatinib (GW572016) in combination with oxaliplatin/fluorouracil/leucovorin (FOLFOX4) in patients with solid tumors
    Siegel-Lakhai, Wandena S.
    Beijnen, Jos H.
    Vervenne, Walter L.
    Boot, Henk
    Keessen, Marianne
    Versola, Melissa
    Koch, Kevin M.
    Smith, Deborah A.
    Pandite, Lini
    Richel, Dirk J.
    Schellens, Jan H. M.
    CLINICAL CANCER RESEARCH, 2007, 13 (15) : 4495 - 4502
  • [10] A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancer.
    Blackwell, KL
    Kaplan, EH
    Franco, SX
    Marcom, PK
    Maleski, JE
    Sorensen, MJ
    Berger, MS
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 196S - 196S
12345